Immunotech Biopharm Ltd. announce that the Company has completed the first patient enrolment for its Phase II clinical trial for CAR-T-19 injection ("CAR-T-19 Injection") in the PRC, which marked a key milestone of the Group's development in its product pipeline. CAR-T-19 Injection is indicated for the treatment of pediatric and young adult patients up to and including the age of 25 with relapsed/refractory B cell acute lymphoblastic leukaemia ("B-ALL"). Based on the progress of clinical trial for CAR-T-19 Injection, it is expected that the target patient enrolment would complete by the end of 2025 and the preliminary analysis and results would be published in the first half of 2026.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.31 HKD | -1.78% | -4.06% | -33.80% |
Mar. 29 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
Mar. 28 | Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.80% | 218M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 6978 Stock
- News Immunotech Biopharm Ltd
- Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection